Harrow, Inc.HROW stock score: 57/100
$32.13 · -0.09% · Scored Nov 19, 2026
- Technical
- 51
- Fundamental
- 58
- News
- 53
The reading
Harrow (HROW) scores 57 out of 100, which reads neutral, higher than 66% of Healthcare stocks and 66% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 58, technicals 51.
Among the fundamentals, Price Target at 100 and Revenue Growth (5-Year) at 100 score highest, while Earnings Growth (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 56 and contrarian oscillators 39.
News sentiment is neutral at 53; it is shown, not counted in the composite.
Since Aug 22, 2026 the composite has ranged from 41 to 57, and it is up 3 points over the period.
About Harrow
Harrow (HROW) is an eyecare pharmaceutical company that sells prescription medicines used by ophthalmologists and optometrists in the United States. Its branded products include VEVYE, a treatment for dry eye disease, IHEEZO, a topical anesthetic gel used during eye procedures, and TRIESENCE, an injectable steroid used in eye surgery and for certain inflammatory conditions. The company has built its portfolio largely by acquiring ophthalmic products from larger drugmakers, including the dry eye nasal spray TYRVAYA, and it also sells a range of older branded eye drops for inflammation, infection and other eye conditions. Harrow sells to wholesalers and specialty distributors, and its products are prescribed by eyecare professionals and administered in clinics and surgical centers. The company earns money from product sales, supported by its own sales force and patient access programs.
Harrow competes with larger eyecare companies such as Alcon and Bausch + Lomb, along with drugmakers that sell dry eye treatments and generic ophthalmic drugs. Its edge rests on a focused sales force that calls on eyecare professionals, a broad product portfolio in a specialized field and a record of acquiring and relaunching established products. Investors who follow HROW stock tend to watch prescription growth for VEVYE and sales of IHEEZO and TRIESENCE. Gross-to-net pricing and reimbursement are closely followed. Integration of acquired products, operating expenses, debt and cash flow are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward HROW’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
58Pulling it up
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
5-year revenue growth analyzes long-term sales trajectory and consistency.
Annual revenue growth tracks year-over-year sales expansion.
Holding it back
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
5-year earnings growth evaluates long-term profit trajectory and consistency.
EV/EBITDA compares the whole company's value, debt included, with its operating earnings before depreciation.
38 weighted scorers; 1 had no data today and are left out rather than counted as zero.
Technical · daily
49Pulling it up
Percentage Price Oscillator shows the difference between two moving averages as a percentage.
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
- VWAP100
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
Holding it back
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Where the close sits against its 200-day SMA.
Where the close sits against its 100-day SMA.
61 weighted scorers; 4 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 53
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 59 | 1 |
| Daily | 49 | 3 |
| Weekly | 37 | 2 |
| Monthly | 53 | 2 |
| Quarterly | 62 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 57 |
| Nov 18, 2026 | 56 |
| Nov 17, 2026 | 55 |
| Nov 16, 2026 | 55 |
| Nov 15, 2026 | 55 |
| Nov 14, 2026 | 55 |
| Nov 13, 2026 | 55 |
| Nov 12, 2026 | 55 |
| Nov 11, 2026 | 46 |
| Nov 10, 2026 | 48 |
| Nov 8, 2026 | 41 |
| Nov 7, 2026 | 41 |
| Nov 6, 2026 | 41 |
| Nov 5, 2026 | 41 |
| Nov 4, 2026 | 44 |
| Nov 3, 2026 | 44 |
| Nov 2, 2026 | 43 |
| Nov 1, 2026 | 43 |
| Oct 31, 2026 | 43 |
| Oct 30, 2026 | 43 |
| Oct 29, 2026 | 46 |
| Oct 28, 2026 | 46 |
| Oct 27, 2026 | 45 |
| Oct 26, 2026 | 45 |
| Oct 25, 2026 | 44 |
| Oct 24, 2026 | 44 |
| Oct 23, 2026 | 44 |
| Oct 22, 2026 | 43 |
| Oct 21, 2026 | 43 |
| Oct 20, 2026 | 44 |
| Oct 19, 2026 | 42 |
| Oct 18, 2026 | 42 |
| Oct 17, 2026 | 42 |
| Oct 16, 2026 | 41 |
| Oct 15, 2026 | 43 |
| Oct 14, 2026 | 41 |
| Oct 13, 2026 | 42 |
| Oct 12, 2026 | 43 |
| Oct 11, 2026 | 44 |
| Oct 10, 2026 | 44 |
| Oct 9, 2026 | 44 |
| Oct 8, 2026 | 44 |
| Oct 7, 2026 | 45 |
| Oct 6, 2026 | 44 |
| Oct 5, 2026 | 43 |
| Oct 4, 2026 | 44 |
| Oct 3, 2026 | 44 |
| Oct 2, 2026 | 43 |
| Oct 1, 2026 | 43 |
| Sep 30, 2026 | 43 |
| Sep 29, 2026 | 44 |
| Sep 28, 2026 | 43 |
| Sep 27, 2026 | 44 |
| Sep 26, 2026 | 44 |
| Sep 25, 2026 | 44 |
| Sep 24, 2026 | 45 |
| Sep 23, 2026 | 46 |
| Sep 22, 2026 | 46 |
| Sep 21, 2026 | 45 |
| Sep 20, 2026 | 44 |
| Sep 19, 2026 | 44 |
| Sep 18, 2026 | 44 |
| Sep 17, 2026 | 44 |
| Sep 16, 2026 | 44 |
| Sep 15, 2026 | 44 |
| Sep 14, 2026 | 44 |
| Sep 13, 2026 | 44 |
| Sep 12, 2026 | 44 |
| Sep 11, 2026 | 44 |
| Sep 10, 2026 | 45 |
| Sep 9, 2026 | 46 |
| Sep 8, 2026 | 48 |
| Sep 7, 2026 | 48 |
| Sep 6, 2026 | 49 |
| Sep 5, 2026 | 49 |
| Sep 4, 2026 | 49 |
| Sep 3, 2026 | 47 |
| Sep 2, 2026 | 50 |
| Sep 1, 2026 | 47 |
| Aug 31, 2026 | 47 |
| Aug 30, 2026 | 47 |
| Aug 29, 2026 | 47 |
| Aug 28, 2026 | 47 |
| Aug 27, 2026 | 48 |
| Aug 26, 2026 | 51 |
| Aug 25, 2026 | 54 |
| Aug 24, 2026 | 50 |
| Aug 23, 2026 | 54 |
| Aug 22, 2026 | 54 |
Key facts
- Market cap
- $1.2B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Beta
- 0.17
- Risk grade (1–10)
- 6
- Next earnings
- Nov 9, 2026
Specialty & Generic Drug Manufacturers peers
| Company | Market cap | Score |
|---|---|---|
| ANIP ANI Pharmaceuticals | $1.6B | 67 |
| ALVO Alvotech | $1.5B | 55 |
| PCRX Pacira BioSciences | $1.5B | 65 |
| PAHC Phibro Animal Health | $1.4B | 63 |
| AMPH Amphastar Pharmaceuticals | $1.2B | 62 |
| CRON Cronos Group | $1.1B | 59 |
All Specialty & Generic Drug Manufacturers stocks, highest-scored first
Questions
What is HROW's stock rating today?
HROW scores 57/100 (Neutral) as of Nov 19, 2026: technical 51, fundamental 58, and news sentiment 53, which is shown but not counted. Scores are recomputed every night.
What does Harrow do?
Harrow (HROW) is an eyecare pharmaceutical company that sells prescription medicines used by ophthalmologists and optometrists in the United States. Its branded products include VEVYE, a treatment for dry eye disease, IHEEZO, a topical anesthetic gel used during eye procedures, and TRIESENCE, an injectable steroid used in eye surgery and for certain inflammatory conditions.
Is HROW stock a buy?
The score is not a buy or sell recommendation. A 57 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the HROW score calculated?
99 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 61 technical on the daily chart, with 5 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/hrow/"><img src="https://stocksscores.com/stocks/hrow/badge.svg" alt="HROW stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/hrow/)